{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027101","form_type":"8-K","ticker":"NSPR","cik":"0001433607","company_name":"InspireMD, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.910990+00:00","generated_at":"2026-06-12T01:28:31.042457+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"InspireMD reports Q2 revenue up 9.6% to $1.65M; secures up to $113.6M private placement","bullets":["Closed transformational private placement: $42.2M upfront, up to $71.4M additional on milestone warrants.","Completed enrollment in C-Guardians IDE trial; anticipates PMA submission in H2 2024.","Q2 CGuard EPS revenue $1.65M (+9.6% YoY); units sold 2,804 (+7.8% YoY).","Net loss $5.08M ($0.24 per share) vs $4.64M ($0.59) in Q2 2022.","Cash $47M as of June 30, up from $17.8M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027101","json":"https://secwatch.observer/filing/0001493152-23-027101.json","markdown":"https://secwatch.observer/filing/0001493152-23-027101.md","text":"https://secwatch.observer/filing/0001493152-23-027101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1433607/000149315223027101/0001493152-23-027101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1433607/000149315223027101/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:28:31.042457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e033084852baa61d8f2235db23445a3d47280cb","claim":"InspireMD, Inc. reported the six months ended June 30, 2023 results: revenue $2,888,000, net income $9,333,000, EPS $0.64 per basic and diluted share.","evidence_excerpt":"after deducting transaction expenses. Financial Results for the Six Months ended June 30, 2023 For the six months ended June 30, 2023, revenue increased by $174,000, or 6.4%, to $2,888,000, from $2,714,000 during the six months ended June 30, 2022. This increase was predominantly driven by a 8.3% increase in sales volume of CGuard EPS from $2,666,000 during the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1433607/000149315223027101/0001493152-23-027101-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Revenue","value":"$2,888,000"},{"label":"Net income","value":"$9,333,000"},{"label":"EPS","value":"$0.64 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a1a0d11d7394337757f13512c72fb590729786fc","claim":"InspireMD, Inc. reported the three months ended June 30, 2023 results: revenue $1,649,000, net income $5,077,000, EPS $0.24 per basic and diluted share.","evidence_excerpt":"performed with its CGuard Prime CAS stent delivery platform as part of C-Guardians trial enrollment. ● Generated record CGuard revenue for the second quarter 2023 of $1,649,000, a 9.6 % increase over the same period in 2022 and a 33% increase over the first quarter of 2023. ● Sold 2,804 CGuard EPS stent systems in the second quarter of 2023, as compared","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1433607/000149315223027101/0001493152-23-027101-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended June 30, 2023"},{"label":"Revenue","value":"$1,649,000"},{"label":"Net income","value":"$5,077,000"},{"label":"EPS","value":"$0.24 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}